(Q39744551)

English

Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

9 November 2017

Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments (English)

1 reference

Europe PubMed Central

PMC publication ID

9 November 2017

rheumatoid arthritis

0 references

1 reference

based on heuristic

inferred from title

Jeffrey R Curtis

4

object named as

Jeffrey R Curtis

1 reference

Europe PubMed Central

PMC publication ID

9 November 2017

Sasha Bernatsky

3

object named as

Sasha Bernatsky

1 reference

Europe PubMed Central

PMC publication ID

9 November 2017

author name string

Fenglong Xie

1

1 reference

Europe PubMed Central

PMC publication ID

9 November 2017

Huifeng Yun

2

1 reference

Europe PubMed Central

PMC publication ID

9 November 2017

publication date

23 May 2016

1 reference

Europe PubMed Central

PMC publication ID

9 November 2017

Arthritis & Rheumatology

1 reference

Europe PubMed Central

PMC publication ID

9 November 2017

68

1 reference

Europe PubMed Central

PMC publication ID

9 November 2017

11

1 reference

Europe PubMed Central

PMC publication ID

9 November 2017

2612-2617

1 reference

Europe PubMed Central

PMC publication ID

9 November 2017

Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5538140

17 June 2018

Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5538140

17 June 2018

Increased incidence and impact of upper and lower gastrointestinal events in patients with rheumatoid arthritis in Olmsted County, Minnesota: a longitudinal population-based study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5538140

17 June 2018

Validation of ICD-9-CM codes to identify gastrointestinal perforation events in administrative claims data among hospitalized rheumatoid arthritis patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5538140

17 June 2018

Integrated safety in tocilizumab clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5538140

17 June 2018

Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5538140

17 June 2018

Validation of rheumatoid arthritis diagnoses in health care utilization data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5538140

17 June 2018

The incidence of gastrointestinal perforations among rheumatoid arthritis patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5538140

17 June 2018

Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5538140

17 June 2018

A novel composite endpoint to evaluate the gastrointestinal (GI) effects of nonsteroidal antiinflammatory drugs through the entire GI tract

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5538140

20 August 2018

Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5538140

20 August 2018

Identifiers

10.1002/ART.39761

1 reference

Europe PubMed Central

PMC publication ID

9 November 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

9 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

9 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39744551&oldid=2089270187"